{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:14:00Z","timestamp":1791335640887,"version":"4.3.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Hellenic Thoracic Society"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.cyto.2018.08.006","type":"journal-article","created":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T14:48:04Z","timestamp":1536331684000},"page":"99-106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Role of angiopoietins in mesothelioma progression"],"prefix":"10.1016","volume":"118","author":[{"given":"Sophia","family":"Magkouta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Androniki","family":"Kollintza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalampos","family":"Moschos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalini","family":"Spella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Skianis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostolos","family":"Pappas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Eleni","family":"Vazakidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Stathopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Kalomenidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 5","key":"10.1016\/j.cyto.2018.08.006_b0005","doi-asserted-by":"crossref","first-page":"v31","DOI":"10.1093\/annonc\/mdv199","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Baas","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cyto.2018.08.006_b0010","first-page":"11","article-title":"The carcinogenic effect of various multi-walled carbon nanotubes (MWCNTs) after intraperitoneal injection in rats","volume":"20","author":"Rittinghausen","year":"2014","journal-title":"Part Fibre Toxicol."},{"issue":"7","key":"10.1016\/j.cyto.2018.08.006_b0015","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/cas.12954","article-title":"Multiwalled carbon nanotubes intratracheally instilled into the rat lung induce development of pleural malignant mesothelioma and lung tumors","volume":"107","author":"Suzui","year":"2016","journal-title":"Cancer Sci."},{"issue":"4","key":"10.1016\/j.cyto.2018.08.006_b0020","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1586\/14737140.2016.1162100","article-title":"A catalogue of treatment and technologies for malignant pleural mesothelioma","volume":"16","author":"Schunselaar","year":"2016","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.cyto.2018.08.006_b0025","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"French Cooperative Thoracic Intergroup (IFCT) Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.cyto.2018.08.006_b0030","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/nrc2894","article-title":"Targeting the ANGPT-TIE2 pathway in malignancy","volume":"10","author":"Huang","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.cyto.2018.08.006_b0035","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1172\/JCI58196","article-title":"The yin, the yang, and the angiopoietin-1","volume":"121","author":"Saharinen","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cyto.2018.08.006_b0040","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1182\/blood-2004-09-3531","article-title":"Angiopoietins can directly activate endothelial cells and neutrophils to promote proinflammatory responses","volume":"105","author":"Lemieux","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.cyto.2018.08.006_b0045","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1242\/jcs.01653","article-title":"The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism","volume":"15","author":"Scharpfenecker","year":"2005","journal-title":"J. Cell Sci."},{"issue":"5","key":"10.1016\/j.cyto.2018.08.006_b0050","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1183\/09031936.00154009","article-title":"A novel clinical role for angiopoietin-1 in malignant pleural mesothelioma","volume":"36","author":"Tabata","year":"2010","journal-title":"Eur. Respir. J."},{"issue":"8","key":"10.1016\/j.cyto.2018.08.006_b0055","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/resp.12604","article-title":"Temsirolimus targets multiple hallmarks of cancer to impede mesothelioma growth in vivo","volume":"20","author":"Vazakidou","year":"2015","journal-title":"Respirology"},{"issue":"31","key":"10.1016\/j.cyto.2018.08.006_b0060","doi-asserted-by":"crossref","first-page":"21783","DOI":"10.18632\/oncotarget.25004","article-title":"Targeting Tie-2\/angiopoietin axis in experimental mesothelioma confers differential responses and raises predictive implications","volume":"9","author":"Magkouta","year":"2018","journal-title":"Oncotarget"},{"issue":"7(15)","key":"10.1016\/j.cyto.2018.08.006_b0065","doi-asserted-by":"crossref","first-page":"20249","DOI":"10.18632\/oncotarget.7912","article-title":"Icmt inhibition exerts anti-angiogenic and anti-hyperpermeability activities impeding malignant pleural effusion","volume":"12","author":"Magkouta","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.cyto.2018.08.006_b0070","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMp1607591","article-title":"Toward a shared vision for cancer genomic","volume":"376","author":"Grossman","year":"2016","journal-title":"Data. N. Eng. J.M."},{"key":"10.1016\/j.cyto.2018.08.006_b0075","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1183\/09031936.00207213","article-title":"Multimodal management of malignant pleural mesothelioma: where are we today?","volume":"44","author":"Van Schil","year":"2014","journal-title":"Eur. Respir. J."},{"issue":"12","key":"10.1016\/j.cyto.2018.08.006_b0080","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1111\/j.1349-7006.2008.00961.x","article-title":"Angiopoietin-1 alters tumor growth by stabilizing blood vessels or by promoting angiogenesis","volume":"99","author":"Satoh","year":"2008","journal-title":"Cancer Sci."},{"issue":"5","key":"10.1016\/j.cyto.2018.08.006_b0085","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/S0002-9440(10)63413-X","article-title":"Angiopoietin-1 promotes tumor angiogenesis in a rat glioma model","volume":"165","author":"Machein","year":"2004","journal-title":"Am. J. Pathol."},{"issue":"473","key":"10.1016\/j.cyto.2018.08.006_b0090","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10144","article-title":"Molecular mechanisms and clinical applications of angiogenesis","volume":"9","author":"Carmeliet","year":"2011","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.cyto.2018.08.006_b0095","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/10739680600775940","article-title":"VEGF and angiopoietin-1 stimulate different angiogenic phenotypes that combine to enhance functional neovascularization in adult tissue","volume":"13","author":"Benest","year":"2006","journal-title":"Microcirculation"},{"issue":"38","key":"10.1016\/j.cyto.2018.08.006_b0100","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1038\/onc.2017.145","article-title":"CECR1-mediated cross talk between macrophages and vascular mural cells promotes neovascularization in malignant glioma","volume":"36","author":"Zhu","year":"2017","journal-title":"Oncogene"},{"issue":"7649","key":"10.1016\/j.cyto.2018.08.006_b0105","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/nature21724","article-title":"Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming","volume":"544","author":"Tian","year":"2017","journal-title":"Nature"},{"issue":"14","key":"10.1016\/j.cyto.2018.08.006_b0110","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1158\/1078-0432.CCR-09-3073","article-title":"Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas","volume":"16","author":"Chae","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.cyto.2018.08.006_b0115","first-page":"198","article-title":"How do angiopoietins Tie in with vascular endothelial growth factors?","volume":"17","author":"Saharinen","year":"2010","journal-title":"Curr. Opin. Hematol."},{"issue":"17","key":"10.1016\/j.cyto.2018.08.006_b0120","doi-asserted-by":"crossref","first-page":"11205","DOI":"10.1073\/pnas.172161899","article-title":"Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo","volume":"99","author":"Lobov","year":"2002","journal-title":"PNAS"},{"issue":"12","key":"10.1016\/j.cyto.2018.08.006_b0125","first-page":"3403","article-title":"Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer","volume":"63","author":"Zhang","year":"2003","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.cyto.2018.08.006_b0130","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S1470-2045(14)70244-X","article-title":"Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial","volume":"15","author":"Monk","year":"2013","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.cyto.2018.08.006_b0135","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.breast.2014.11.003","article-title":"Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: a phase 2 randomized study","volume":"24","author":"Di\u00e9ras","year":"2015","journal-title":"Breast"},{"key":"10.1016\/j.cyto.2018.08.006_b0140","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1200\/JCO.2014.60.6012","article-title":"Trebananib (AMG 386) in combination with sunitinib in patients with metastatic renal cell cancer: an open-label, multicenter. Phase II study","volume":"20","author":"Atkins","year":"2015","journal-title":"J. Clin. Oncol."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466618303417?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466618303417?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T05:36:50Z","timestamp":1604900210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466618303417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":28,"alternative-id":["S1043466618303417"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2018.08.006","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of angiopoietins in mesothelioma progression","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2018.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}